A possible new option for migraine management: Agomelatine

Clinical Neuropharmacology

Volumn 36, Issue 2, 2013, Pages 65-67

  Guglielmo, Riccardo ^a   Martinotti, Giovanni ^b   Di Giannantonio, Massimo ^b   Janiri, Luigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

agomelatine; antidepressants; melatonin; migraine; prophilaxys

Indexed keywords

ACETYLSALICYLIC ACID; AGOMELATINE; AMITRIPTYLINE; AURALGAN; PARACETAMOL; PROPRANOLOL; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ANALGESIA; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR DEPRESSION; MIGRAINE; NAUSEA; PHOTOPHOBIA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; VOMITING;

ACETAMIDES; ADULT; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MELATONIN; MIGRAINE DISORDERS; RECURRENCE;

EID: 84875476348     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182800271     Document Type: Article

References (13)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160.
2. Peres MF, Masruha MR, Zukerman E, et al. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs 2006;15:367-375.
3. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol 2001;21: 605-616.
4. Ramasubbu R, Taylor VH, Samaan Z, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry 2012;24:91-109.
5. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370.
6. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30:135-144.
7. Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents 2011;25:109-114.
8. Martinotti G, Sepede, G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder subjects: a pilot study. J Clin Psychopharmacol 2012;32:487-491.
9. De Berardis D, Di Iorio G, Acciavatti T, et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011;10: 119-132.
10. Peres MF, Zukerman E, da Cunha Tanuri F, et al. Melatonin 3 mg is effective for migraine prevention. Neurology 2004;63:757.
11. Delagrange P, Boutin JA. Therapeutic potential of melatonin ligands. Chronobiol Int 2006;23:413-418.
12. Alstadhaug KB, Odeh F, Salvesen R, et al. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology 2010;75:1527-1532.
13. Claustrat B, Brun J, Geoffriau M, et al. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997;17:511-517.